3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Skin Neoplasms
1
Multiple Sclerosis, Relapsing-Remitting
1
Multiple Sclerosis
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Gliosarcoma
1
Glioblastoma
1
Carcinoma, Basal Cell
1
Interventions
Peripheral Blood Stem Cell Transplantation
32
fludarabine phosphate
29
Cyclophosphamide
26
Whole-Body Irradiation
21
Cyclosporine
20
Busulfan
20
Mycophenolic Acid
19
Tacrolimus
16
Antilymphocyte Serum
14
Methotrexate
13
romidepsin
12
Etoposide
12
Filgrastim
11
Melphalan
9
Psychiatric Rehabilitation
8
Methylprednisolone
8
Dexamethasone
8
Bexarotene
8
Vorinostat
7
Flow Cytometry
7
Therapeutics
6
Radiotherapy
6
Calcium Dobesilate
6
Brentuximab Vedotin
6
Bortezomib
6
Alemtuzumab
6
sargramostim
5
fludarabine
5
denileukin diftitox
5
Polymerase Chain Reaction
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, T-Cell, Cutaneous
×
Dimethyl Fumarate
×
Clear all
NCT02546440
2023-03-31
DMF-CTCL
Universitätsmedizin Mannheim
Phase 2
Completed
25 enrolled